RESULTS: Compared to patients with TC, significantly more patients with TCD were male, had larger tumours, and displayed a greater proportion of lymph node metastases. However, overall survival was similar (60.7% 5-year survival for TC, 80.7% for TCD, P = 0.159), as was disease-free survival (41.1% 5-year survival for TC, 37.6% for TCD, P = 0.696) and patterns of relapse. Multiple Cox regression analysis identified younger patients [hazard ratio (HR) 1.018; 95% confidence interval (CI) 1.000-1.035; P = 0.047], more completeness of resection (HR 1.424; 95% CI 1.105-1.836; P = 0.006), adjuvant radiotherapy (HR 0.455; 95% CI 0.276-0.751; P = 0.002), and no adjuvant chemotherapy (HR 1.799; 95% CI 1.017-3.183; P = 0.044) as independent factors predicting better overall survival. Completeness of resection (HR 1.258; 95% CI 1.022-1.548; P = 0.031) and TNM stage (HR 1.479; 95% CI 1.107-1.977; P = 0.008) were independent predictors of disease-free survival. Propensity matching produced 46 patients in each group and no significant difference on overall survival or diseasefree survival was found.
INTRODUCTION
Thymic epithelial neoplasms are a rare but well-established group of organ-specific neoplasms with varying malignant potential that comprise thymomas, thymic carcinomas (TC) and thymic neuroendocrine tumours (primarily thymic carcinoid, TCD) [1] . It is recognized that TC behaves more aggressively than thymoma [2] , but the comparative clinical characteristics of TC and TCD have not been well investigated. As such, it is currently unclear whether these two distinctive histological subtypes would benefit from tailored treatment strategies.
Here, we retrospectively analyzed a cohort of 287 patients with TC and 56 patients with TCD to assess factors that may determine clinical features, survival, and interval and pattern of disease relapse for each tumour type.
PATIENTS AND METHODS

Study design and treatment
Study participants were selected from patients who had pathologically confirmed TC or TCD and were treated in the Shanghai Chest Hospital between February 2003 and April 2014. Patient characteristics and clinical outcomes were extracted from medical records. All cases were reclassified according to the World Health Organization (WHO) 2015 standards [3] . Briefly, TC is defined as a tumour showing clear-cut cytological atypia and loss of the characteristic organotypical features of differentiation of normal thymus and lacking inmmature T lymphocytes. The expression of CD5 or CD117 is positive immunostainly. TCD is a well-differentiated neuroendocrine carcinoma including typical carcinoid (<2 mitoses/2 mm 2 ; no necrosis) proposed tumour-node-metastasis (TNM) system [1] . Indications for neoadjuvant therapy or adjuvant treatment were based on the surgeon's discretion, such as the tumour invasion extent and associated possibility of radical extirpation, or clinical stage, perception of complete resection, the risk of recurrence, and clinical appropriateness. Since July 2007, this clinical information has been deposited in a prospective clinical database of thymic tumours, maintained by our Institution. In total, 343 patients (287 TC and 56 TCD) had sufficient clinical and pathologic data to be included in the study.
Outpatient follow-up occurred at 3 month intervals for the first year, 6 month intervals for the subsequent year, and then yearly. Survival data not available from medical records were obtained by contacting patients by telephone or mail. Overall survival was defined as the interval between operation and the date of death, or the last outpatient follow-up. Disease-free survival was defined as the interval from resection to the date of proven tumour progression pathologically or clinically. All outcome measures are reported as defined by ITMIG guidelines [5] . Recurrence was specified as local recurrence (anterior mediastinum), regional recurrence (intrathoracic, not contiguous with thymus), and distant recurrence (intrapulmonary or extrathoracic). Recurrence was diagnosed by biopsy or by unequivocal tumour mass (newly appearing metastases or local recurrence) and growth during follow-up. The last general follow-up of survivors was undertaken at the end of October 2016.
Approval for this study was granted by the Institutional review board, along with a waiver for the requirement of patient consent.
Statistical analysis
Statistical analysis was performed with Statistical Package for Social Sciences version 21.0 software (SPSS, Inc., Chicago, IL). Continuous data are summarized by mean ± standard deviation and categoric data by frequencies and percentages. The Fisher's exact and v 2 tests were used for categoric variables while the Wilcoxon rank sum and the independent samples t-tests were used for continuous variables. The survival probabilities were calculated by the Kaplan-Meier method from the date of the operation until death or loss to follow-up. Differences in survival were evaluated with the log-rank test. Clinical variables were also included in the multiple Cox regression analysis and probability values of less than 0.05 were considered significant. We also used a one-to-one matching analysis between TC and TCD patients on the basis of propensity score to minimize bias of nonrandom allocation.
RESULTS
Clinical features
Characteristics of the study population are summarized in Table 1 . Compared to patients with TC, patients with TCD were predominantly male (83.9% vs 61.7%, P = 0.001), had larger tumours (9.1 cm vs 7.5 cm, P = 0.001), presented more frequently with lymph nodes metastases (76.2% (16/21) vs 48.4% (46/95), P = 0.045), and experienced less adjuvant therapies. Differences in age, preoperative symptom, Masaoka-Koga stage, IASLC/ITMIG proposed TNM stage, and completeness of resection were not significant.
Follow-up and survival
Follow-up data was complete for 91.6% (263 of 287) of TC patients and 89.3% (50 of 56) of TCD patients. The median duration of follow-up was 47.0 months (range 1 to 173 months) for TC and 55.0 months (range 2 to 152 months) for TCD.
For TC patients, overall survival was 63.7% at 5 years and 48.4% at 10 years. Five-and 10-year disease-free survival was 41.1 and 32.4%, respectively. Median overall survival was 100.6 ± 5.3 months and median time to recurrence was 67.3 ± 4.2 months. A total of 150 patients (57.0%) experienced recurrence after treatment (Table 1 ). Among these, 108 patients (72.0%) suffered distant relapse which involved bone (42), lung (41), liver (27), extrathoracic lymph node (11), adrenal gland (5), brain (4), skin (4), and kidney (1) . At the end of the study, 107 patients were alive without relapse, 53 were alive with disease progression, 98 patients had died with the disease, and 5 died without tumour-specific causes.
Among TCD patients, overall survival was 80.7% at 5 years and 51.9% at 10 years. Five-and ten-year disease-free survival was 37.5 and 16.5%, respectively. Median overall survival was 105.0 ± 9.2 months and median time to recurrence was 55.7 ± 7.0 months. A total of 33 patients (66.0%) experienced recurrence after treatment (Table 1 ). Among these, 22 patients (66.7%) suffered distant relapse which developed in the bone (18) , lung (4), liver (3), extrathoracic lymph node (4), pancreas (2), adrenal gland (2) larynx and kidney (1 each). At the end of the study, 15 patients were alive without relapse, 20 were alive with disease progression, 14 patients had died with the disease, and 1 died without tumour-specific reasons.
There was no difference in overall survival (P = 0.159, Fig. 1 ), disease-free survival (P = 0.696, Fig. 2 ), or patterns of relapse (P = 0.560) between patients with TC and TCD.
Clinical predictors of survival
To identify potential predictors of survival, we performed multiple Cox regression analysis of clinical parameters for TC and TDC patients combined. As shown in Table 2 , overall survival significantly correlated with patients age [hazard ratio (HR) 1.018, P = 0.047], completeness of resection (HR 1.424, P = 0.006), adjuvant radiotherapy (HR 0.455, P = 0.002), and adjuvant chemotherapy (HR 1.799, P = 0.044). Completeness of resection (HR 1.258, P = 0.031) and IASLC/ITMIG proposed TNM stage (HR 1.479, P = 0.008) remained significant predictors of disease-free survival (Table 2) .
Propensity-score analysis
Propensity matching produced 46 patients in each group. The two groups were well matched with respect to age, gender, preoperative symptom, surgical procedures, neoadjuvant therapy, adjuvant treatment, completeness resection, lymph node Table 1 . Median overall survival was 91.9 ± 10.5 months and median time to recurrence was 76.1 ± 10.2 months in TC patients, and 101.5 ± 9.6 and 58.9 ± 7.6 months in TCD patients, respectively. Analysis of the propensity-matched group for survival demonstrate that there was no significant difference in overall survival (P = 0.220, Fig. 3 ) or disease-free survival (P = 0.675, Fig. 4 ).
DISCUSSION
The objective of this study was to compare clinical features and predictors of survival between patients with TC and TCD. We found that TCD tumours were larger, affected more male patients, and had a greater proportion of lymph node metastasis. However, no difference was observed in overall survival, diseasefree survival or relapse pattern between the two tumour types. TCD is rare and only a few case series have been reported [6] . Rosai and Higa are credited with distinguishing TCD from conventional thymomas [7] , but the prognosis and relative behaviour of these rare carcinomas remains unknown. In our study, more than half of all patients with TC and TCD relapsed after initial treatment and the majority of these presented with distant progression (72.0% in TC and 66.7% in TCD, respectively). The aggressive biology of these tumours denotes the importance of systemic therapy including once diagnosis is established, as suggested by Huang et al. [2] .
In 2014, IASLC and ITMIG jointly published a proposal for the forthcoming edition of the TNM classification of thymic epithelial neoplasms [1] . They recommended that this proposed staging system is also applicable to TC and TCD. In our study, we applied their staging to all patients, in addition to the traditional Masaoka-Koga system. In keeping with other studies [8] , the Masaoka-Koga clinical stage did not correlate with overall survival or disease-free survival. The IASLC/ITMIG proposed TNM system, however, clearly identified prognostically distinct groups of patients with regard to disease-free survival. Our results support the appropriateness of the IASLC/ITMIG recommendations in the clinic. Of note, both IASLC/ITMIG and Masaoka-Koga staging failed to predict overall or disease-free survival for TC or TCD when considered separately (data of TCD in our previous paper [9] ), though this is likely due to the small sample size.
Our multiple Cox regression analysis demonstrated that completeness of resection was a strong independent predictor of both overall and disease-free survival. This reiterates the importance of complete resection for these tumours, concurrent with other published studies [5, [10] [11] [12] .
We also explore the pattern and factors of lymph node metastasis. In our TC group, 33.1% patients (95/287) underwent lymph node retrieval and 48.4 patients (46/95) were positive. A total of 272 lymph nodes were harvested. The mean number of dissected lymph nodes per patient was 2.3 ± 1.7 (range 1 to 10). The rates of node metastasis for each T stage were 33.3% at T1 (5/15; N1 = 4, N2 = 1, respectively), 28.6% at T2 (2/7; N1 = 2, N2 = 0, respectively), and 53.4% at T3 (31/58; N1 = 15, N2 = 16, respectively). We could not find a significant relationship between lymph node metastasis and advanced T category (P = 0.470). The rates of node metastasis for the M stages were 39.5% (30/76) for M0 and 78.9% (15/19) for M1. Our patients at stage M1 showed a significantly higher rate of node metastasis (P = 0.008). In our TCD group, 37.5% patients (21/56) underwent lymph node retrieval and 76.2% patients (16/21) were positive. A total of 38 lymph nodes were harvested. The mean number of dissected lymph nodes per patient was 1.8 ± 1.0 (range 1 to 4). The rates of node metastasis for each T stage were 50.0% at T1 (3/6; N1 = 3, N2 = 0, respectively), 66.7% at T2 (2/3; N1 = 2, N2 = 0, respectively), and 90.9% at T3 (10/11; N1 = 5, N2 = 5, respectively). But we could not find a significant relationship between lymph node metastasis and advanced T category (P = 0.160). The rates of node metastasis for the M stages were 73.3% (11/15) for M0 and 83.3% (5/6) for M1. Our patients at stage M1 did not show a significantly higher rate of node metastasis (P = 0.880). In 2011, the ITMIG submitted a recommendation for lymph node dissection in thymic malignancies [13] . From then on, lymph node metastasis is becoming one of the most focused issues in thymic tumours [14] [15] [16] [17] [18] [19] . In 2014, the ITMIG/IASLC proposed a new lymph node map specific to thymic tumours [20] . It was used for grouping and staging the lymph nodes in our study. Compared to the traditional Masaoka-Koga stage [HR 1.038; 95% confidence interval (95% CI) 0.695-1.551, P = 0.855], which does not consider the factor of lymph nodes metastasis, the proposed TNM stage behaved better on predicting disease-free survival in our study (HR 1.479; 95% CI 1.107-1.977; P = 0.008). But both stage systems performed worse on predicting overall survival in our study, though the TNM stage had an advantage over the Masaoka-Koga counterpart [HR 1.259 (0.929-1.988) vs HR 1.013 (0.600-1.710)]. Our sample numbers and events were also small and inadequate for powered statistical analyses. The routine dissection of lymph nodes is reiterated to implementation to get better insight on this issue.
Given the bias inherent with retrospective studies performed within a single center, our results should be interpreted with caution. In addition, the duration of follow-up was limited. However, our study is strengthened by a large sample size drawn from a recent time period that reflects current treatment standards and tumour classification. In addition, 29 of the 343 patients (8.5%) were managed without surgery, making our findings generalizable. P-values were obtained using the log-rank test. TC: thymic carcinomas; TCD: thymic carcinoids.
We conclude that although TC and TCD are histologically distinct entities with differential clinical features, patients still experience similar overall survival, recurrence interval, and patterns of relapse. Our data also emphasize the importance of complete resection in survival rates for both thymic malignancies.
